Recently, researchers combined the SMO inhibitor MRT-92 and a Proteolysis Targeted Chimeras (PROTACs)-derived BRD4 degrader (MZ1), to treat the tumor and found that it remarkably suppressed tumor growth [162]. Here, BRD4 is linked to neoplasm.